RxDoctor Payments Data

Dali Fan, MD

Cardiovascular Disease · Sacramento, CANPI 1245289545

Payments from drug & device makers

$60,137in general payments, 2019–2025

Across 182 payments — averaging $330.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$25K
  • Siemens Medical Solutions USA, Inc.$15K
  • Biotronik Inc.$6K
  • Sanofi-aventis U.S. LLC$5K
  • Impulse Dynamics (USA) Inc.$5K
  • E.r. Squibb & Sons, L.L.C.$806
  • plus $4K from 21 others

What the payments were for

  • Consulting fees$20,20742%
  • Speaking & faculty fees$7,16815%
  • Travel & lodging$11,80824%
  • Food & beverage$9,14919%
  • Education$1730%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,137 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$191,268
Medicare patients
2,021
Services billed
4,124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban149$198,390
XareltoRivaroxaban41$58,390
Metoprolol Succinate211$4,512
Flecainide Acetate28$2,543
Nifedipine ErNifedipine43$2,004
Valsartan16$1,857
Atorvastatin Calcium68$639
Carvedilol59$606
Losartan Potassium58$587
Rosuvastatin Calcium26$553
Amlodipine Besylate46$508
Metoprolol Tartrate36$480
SotalolSotalol Hcl20$384
Amiodarone Hcl20$383
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$466$198,390149 claims
Johnson & JohnsonXarelto$308$58,39041 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →